CD4 and cancer: It can be concluded that the EEROP could modulate the immune response by (1) downregulating IL-1, IL-6, TNF-α, IFN-γ, TGF-β, and IL-10, to prevent the overexpression of pro-inflammatory cytokines, (2) increasing the activity of CD4+ and CD8+ T cells, to improve the immune response against cancer, and (3) protecting the epithelium of mammary gland from thickening because of cancer cell proliferation.